Literature DB >> 23378010

Evaluation of the QMS® Teicoplanin Immunoassay (ThermoFisher Scientific) on Cobas® 8000 System (Roche Diagnostics) and comparison to fluorescence polarization immunoassay for the determination of teicoplanin concentrations in human plasma.

Eric Dailly1, François Fraissinet, Guillaume Deslandes, Régis Bouquié, Pascale Jolliet.   

Abstract

BACKGROUND: The performances of the QMS(®) Teicoplanin immunoassay recently developed on Cobas(®) 6000/8000 systems were evaluated and compared to a fluorescence polarization immunoassay (FPIA) [Teicoplanin Innofluor(®) Assay (Thermo Fisher Scientific, Indianapolis, IN)] on FLX analyzer (Abbott Laboratories, Abbott Park, IL)].
METHODS: The validation was performed according to the Cofrac (French Accreditation Committee) document SH GTA 04. For the comparison, 48 plasma samples were analyzed by FPIA and QMS assays.
RESULTS: The QMS assay is accurate (intra assay and inter assay inaccuracy ≤ 2.4%) and precise (intra assay and inter assay imprecision ≤ 10.2%). A linear relationship [QMS = 1.0319 × FPIA - 2.8518, r(2) = 0.9246 (P < 0.001)] between FPIA and QMS was found. In the Bland-Altman plots, no systematic bias was found even if QMS results trends to be lower (mean of the ratio QMS concentration/FPIA concentration = 0.91).
CONCLUSION: These results between QMS and FPIA are consistent, which indicates that QMS(®) Teicoplanin immunoassay on Cobas(®) 8000 System is an alternative to FPIA.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378010      PMCID: PMC6807496          DOI: 10.1002/jcla.21567

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  7 in total

1.  Assay of teicoplanin in serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay.

Authors:  Steven J McCann; Leslie O White; Brian Keevil
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

2.  Improved quantitative determination of total and unbound concentrations of six teicoplanin components in human plasma by high performance liquid chromatography.

Authors:  Kazuhiko Hanada; Akiko Kobayashi; Yumi Okamori; Toshimi Kimura; Hiroyasu Ogata
Journal:  Biol Pharm Bull       Date:  2005-10       Impact factor: 2.233

3.  Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method.

Authors:  Francis H Y Fung; Jonathan C Y Tang; John P P Hopkins; John J Dutton; Lisa M Bailey; Andrew S Davison
Journal:  Ann Clin Biochem       Date:  2012-08-08       Impact factor: 2.057

4.  Comparison of fluorescence polarization immunoassay and high-performance liquid chromatography methods for assay of teicoplanin: can correlation be improved?

Authors:  Siamak Davani; Michel Bérard; Bernard Royer; Jean-Pierre Kantelip; Patrice Muret
Journal:  Pathol Biol (Paris)       Date:  2004-12

Review 5.  Teicoplanin: chemical, physico-chemical and biological aspects.

Authors:  C Coronelli; G G Gallo; B Cavalleri
Journal:  Farmaco Sci       Date:  1987-10

Review 6.  [Level of evidence for therapeutic drug monitoring of teicoplatin].

Authors:  Audrey Boulamery; Nicolas Venisse; Chantal Le Guellec
Journal:  Therapie       Date:  2011-04-07       Impact factor: 2.070

7.  A critical review of the dosage of teicoplanin in Europe and the USA.

Authors:  A P Wilson; R N Grüneberg; H Neu
Journal:  Int J Antimicrob Agents       Date:  1994-04       Impact factor: 5.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.